Entera Bio Details Warrants: $5.85 Exercise Price Per Share

TL;DR

**Entera Bio filed an 8-K detailing warrants exercisable at $5.85 per share, impacting future dilution.**

AI Summary

Entera Bio Ltd. filed an 8-K on February 2, 2024, disclosing information about its Warrants, which are exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share. This filing, under Regulation FD Disclosure, provides details about the terms of these warrants, which trade under the symbol ENTXW on NASDAQ. For investors, this matters because the exercise price of $5.85 per Ordinary Share sets a benchmark for potential dilution and future capital infusion, impacting the value of existing shares if warrants are exercised.

Why It Matters

Understanding the terms of these warrants, especially the $5.85 exercise price, is crucial for shareholders as it impacts potential future dilution and the company's capital structure.

Risk Assessment

Risk Level: medium — The existence of warrants at a specific exercise price introduces potential dilution risk for existing shareholders if exercised, but also potential capital for the company.

Analyst Insight

Investors should monitor the trading price of ENTXW relative to the $5.85 exercise price and the underlying ordinary shares to assess potential arbitrage opportunities or future dilution impact.

Key Numbers

• $5.85 — Exercise Price per Ordinary Share (This is the price at which each half of an Ordinary Share can be acquired by exercising a Warrant.)

Key Players & Entities

• Entera Bio Ltd. (company) — the registrant filing the 8-K
• $5.85 (dollar_amount) — the exercise price per Ordinary Share for the Warrants
• February 2, 2024 (date) — the date of the earliest event reported in the 8-K filing
• NASDAQ (company) — the exchange where Entera Bio's warrants (ENTXW) are traded
• ENTXW (company) — the trading symbol for Entera Bio's Warrants

Forward-Looking Statements

• The exercise of these warrants could lead to an increase in Entera Bio's outstanding shares. (Entera Bio Ltd.) — high confidence, target: Ongoing

FAQ

Filing Documents

• zk2430865.htm (8-K) — 30KB
• 0001178913-24-000353.txt ( ) — 210KB
• entx-20240202.xsd (EX-101.SCH) — 5KB
• entx-20240202_def.xml (EX-101.DEF) — 18KB
• entx-20240202_lab.xml (EX-101.LAB) — 28KB
• entx-20240202_pre.xml (EX-101.PRE) — 20KB
• zk2430865_htm.xml (XML) — 7KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. As previously reported, on December 22, 2023, Entera Bio Ltd., a company organized under the laws of the State of Israel (the " Company "), consummated a private placement of securities to certain accredited investors and, among other things, entered into a registration rights agreement, obligating the Company to file a registration statement with the Securities and Exchange Commission (" SEC ") to register for resale the Company's ordinary shares issued and sold in the private placement, together with ordinary shares issuable upon exercise of warrants issued and sold in the private placement (collectively, the " Private Placement Securities "). On February 2, 2024, in accordance with its obligations under the registration rights agreement, the Company filed with the SEC a registration statement on Form S-3 to register the resale of the Private Placement Securities. This Current Report on Form 8-K does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ENTERA BIO LTD. Date: February 2, 2024 By: /s/ Miranda Toledano Name: Miranda Toledano Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR